# Daekitech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/daekitech

- Industry: Medical Devices & Equipment
- Headquarters: Santiago, Chile
- Website: www.daekitech.com
- Latest round: Seed (Dec 22, 2017)
- Investors on record: 2

## About

Daekitech specializes in the development and commercialization of high-specificity antibodies for advanced biomedical research, supporting various applications in molecular biology, neurobiology, immunology, and cancer biology.Founded in 2015 in Santiago, Chile, Daekitech focuses on creating specialized antibody products. The company has undergone no significant pivots in its strategy and does not have parent or subsidiary relationships. Amanda Céspedes, the founder, has established the company without previous ventures in the biotechnology sector. Daekitech completed one deal by raising an undisclosed amount of SEED funding from IndieBio and SOSV on December 22, 2017.Daekitech specializes in the development and commercialization of high-specificity antibodies designed for advanced research in various biomedical fields. Their primary product offerings include antibodies such as the Bassoon Antibody: PerCP, TAF10 Rabbit Polyclonal Antibody, Smad2 (Phospho-Ser467) Antibody, IFI44 Antibody, SHOX2 Polyclonal Antibody, Rabbit anti-HOXA13 Antibody, and POK7 Antibody, among others. These antibodies cater to numerous applications, including immunofluorescence, Western blotting, flow cytometry, and chromatin immunoprecipitation, serving as essential tools for researchers investigating synaptic function, transcriptional regulation, immune responses, and cancer biology. Daekitech targets research institutions, universities, and pharmaceutical companies engaged in molecular biology, neurobiology, immunology, and cancer research, serving a global market across North America, Europe, and Asia.Daekitech generates revenue through direct sales of its specialized antibody products to research institutions and laboratories around the world. The transaction structure revolves around direct-to-consumer sales, allowing clients to place orders for specific antibodies according to their research needs. Customers can acquire products through individual purchases or bulk orders, addressing their ongoing research requirements. The pricing aligns with the advanced nature of the products, reflecting the high specificity and rigorous validation each antibody undergoes prior to sale. Flagship products, such as the Bassoon Antibody: PerCP and TAF10 Rabbit Polyclonal Antibody, are highlighted in promotional materials and are significant revenue drivers due to their critical roles in advanced research.Daekitech is planning to expand its product line by developing new antibodies with anticipated launches in the upcoming year. The company aims to penetrate new markets in Europe and Asia by the end of 2023, leveraging recent funding to enhance its research and development capabilities. The funding from the SEED round will support these initiatives, allowing for the creation of innovative antibody products and facilitating market entry.

## Funding rounds

- Seed, Dec 22, 2017 — SOSV, IndieBio

## Investors

- SOSV (https://capitalatlas.ai/funds/sosv) — Seed
- IndieBio (https://capitalatlas.ai/funds/indiebio) — Seed